Cingulate Sets Dec 2026-Jan 2027 CTx-1301 NDA Resubmission Window After CRL
CING sits 50% above its 52-week low of $3.16.
Summary
Cingulate said it expects to resubmit the CTx-1301 NDA to the FDA between December 2026 and January 2027, addressing the June 2026 Complete Response Letter's manufacturing questions, with a potential launch in Q3 2027 if approved.
Key Events · Product Development and Regulatory · CING
-
NDA Resubmission Window Set
Cingulate expects to resubmit the CTx-1301 NDA between December 2026 and January 2027, roughly six to seven months after the June 1, 2026 Complete Response Letter.
-
CRL Issues Largely Resolved
The CRL requested only additional chemistry, manufacturing and controls information and raised no clinical safety or efficacy concerns; the company says the manufacturing work is substantially complete and supporting data is being finalized.
-
Review Clock Depends on FDA Class
The FDA is expected to classify the resubmission as Class 1 (two-month review goal) or Class 2 (six-month review goal); the company cannot assure how it will be classified or that it will be accepted.
-
Launch Targeted for Q3 2027
Subject to approval, Cingulate says commercial launch of CTx-1301 could begin in the third quarter of 2027, with no assurance on timing or occurrence.
Analysis · CING · Life Sciences
The biggest swing factor for a company this size is now on a clock. Cingulate's lead asset, CTx-1301 for ADHD, has been stalled since the FDA's June 1, 2026 Complete Response Letter, which asked only for additional chemistry, manufacturing and controls information and raised no clinical safety or efficacy concerns. This filing puts a date on the fix: the company says the manufacturing work is substantially complete and it expects to resubmit the NDA between December 2026 and January 2027, with a potential commercial launch in the third quarter of 2027 if approved. That converts an open-ended regulatory problem into a defined timeline. The risk is unchanged in kind — the FDA still has to accept the resubmission, classify it as Class 1 (two-month review) or Class 2 (six-month review), and approve — and the company carries a going concern warning previously disclosed in its Q2 10-Q, so financing needs persist while the clock runs.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $4.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.7M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.